维普中文期刊产品整合服务
3篇 您的检索式:作者名="Susan You"
    题名 作者 年代 出处 被引量
1D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function显示文摘Masato Sasaki Christiane B. Knobbe Momoe Itsumi Andrew J. Elia Isaac S. Harris Iok In Christine Chio Rob A. Cairns Susan McCracken Andrew Wakeham Jillian Haight Annick You Ten Bryan Snow Takeshi Ueda Satoshi Inoue Kazuo Yamamoto Myunggon Ko Anjana Rao Kat 2012Genes & Development2012,,18:1
2Rapid increase in colorectal cancer rates in urban Shanghai, 1972-97, in relation to dietary changes 显示文摘Wei-Cheng You Fan Jin Susan Devesa 2002Jouanal of Cancer Epidemiology and Prevention2002,7,2:1
3Cancer screening and management in the transgender population:Review of literature and special considerations for gender affirmation surgery显示文摘BACKGROUND Literature focused on cancer screening and management is lacking in the transgender population.AIM To action to increase contributions to the scientific literature that drives the creation of cancer screening and management protocols for transgender and gender nonconforming(TGNC)patients.METHODS We performed a systematic search of PubMed on January 5th,2022,with the following terms:“TGNC”,OR“transgender”,OR“gender non-conforming”,OR“gender nonbinary”AND“cancer screening”,AND“breast cancer”,AND“cervical cancer”,AND“uterine cancer”,AND“ovarian cancer”,AND“prostate cancer”,AND“testicular cancer”,AND“surveillance”,AND“follow-up”,AND“management”.70 unique publications were used.The findings are discussed under“Screening”and“Management”categories.RESULTS Screening:Current cancer screening recommendations default to cis-gender protocols.However,long-term genderaffirming hormone therapy and loss to follow-up from the gender-specific specialties contribute to a higher risk for cancer development and possible delayed detection.The only known screening guidelines made specifically for this population are from the American College of Radiology for breast cancer.Management:Prior to undergoing Gender Affirmation Surgery(GAS),discussion should address cancer screening and management in the organs remaining in situ.Cancer treatment in this population requires consideration for chemotherapy,radiation,surgery and/or reconstruction.Modification of hormone therapy is decided on a case-by-case basis.The use of prophylactic vs aesthetic techniques in surgery is still debated.CONCLUSION When assessing transgender individuals for GAS,a discussion on the future oncologic risk of the sex-specific organs remaining in situ is essential.Cancer management in this population requires a multidisciplinary approach while the care should be highly individualized with considerations to social,medical,surgical and gender affirming surgery related specifications.Special considerations have to be made during planning for GAS as surgery will alter the anatomy and may render the organ difficult to sample for screening purposes.A discussion with the patient regarding the oncologic risk of remaining organs is imperative prior to GAS.Other special considerations to screening such as the conscious or unconscious will to unassociated with their remaining organs is also a key point to address.We currently lack high quality studies pertinent to the cancer topic in the gender affirmation literature.Further research is required to ensure more comprehensive and individualized care for this population.Juliet C Panichella Sthefano Araya Siddhartha Nannapaneni Samuel G Robinson Susan You Sarah M Gubara Maria T Gebreyesus Theresa Webster Sameer A Patel Alireza Hamidian Jahromi 2023World Journal of Clinical Oncology2023,14,7:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费